Conditions: Multiple Sclerosis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 8
Healthy volunteers: no

Brief summary:
The MRI study is designed to identify possible mechanisms by which alemtuzumab acts to protect the brain from inflammation and how it may enhance repair through remyelination.

Detailed description:
To identify specific changes in T cell subsets and functions in Relapsing Remitting Multiple Sclerosis.

Arms:
arm 1: Single arm, single cohort study, all subjects will be dosed with alemtuzumab.

Interventions: intervention 1: Alemtuzumab
Intervention descriptions: intervention 1: 10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.

Protocol document: